Colorectal carcinoma (CRC) is a disease that causes significant morbidity and mortality worldwide. To improve treatment, new biomarkers are needed to allow better patient risk stratification in terms of prognosis. This study aimed to clarify the prognostic significance of colonic-specific transcription factor special AT-rich sequence-binding protein 2 (SATB2), cytoskeletal protein cytokeratin 7 (CK7), and immune checkpoint molecule programmed death-ligand 1 (PD-L1). We analyzed a cohort of 285 patients with surgically treated CRC for quantitative associations among the three markers and five traditional prognostic indicators (i.e., tumor stage, histological grade, variant morphology, laterality, and mismatch-repair/MMR status). The results showed that loss of SATB2 expression had significant negative prognostic implications relative to overall survival (OS) and cancer-specific survival (CSS), significantly shortened 5 years OS and CSS and 10 years CSS in patients with CRC expressing CK7, and borderline insignificantly shortened OS in patients with PD-L1 + CRC. PD-L1 showed a significant negative impact in cases with strong expression (membranous staining in 50-100% of tumor cells). Loss of SATB2 was associated with CK7 expression, advanced tumor stage, mucinous or signet ring cell morphology, high grade, right-sided localization but was borderline insignificant relative to PD-L1 expression. CK7 expression was associated with high grade and SATB2 loss. Additionally, a separate analysis of 248 neoadjuvant therapy-naïve cases was performed with mostly similar results. The loss of SATB2 and CK7 expression were significant negative predictors in the multivariate analysis adjusted for associated parameters and patient age. In summary, loss of SATB2 expression and gain of CK7 and strong PD-L1 expression characterize an aggressive phenotype of CRC.

Department of Anaesthesia and Intensive Care Medicine 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of General Surgery 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pathology 1st Faculty of Medicine Charles University General University Hospital Prague Czech Republic

Department of Pathology 3rd Faculty of Medicine Charles University University Hospital Kralovske Vinohrady Prague Czech Republic

Department of Pathology and Molecular Medicine 3rd Faculty of Medicine Charles University Thomayer University Hospital Prague Czech Republic

Zobrazit více v PubMed

World Health Organization. Cancer. https://www.who.int/news-room/fact-sheets/detail/cancer. Accessed Dec 2021.

Sung H, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. PubMed DOI

FitzPatrick DR, et al. Identification of SATB2 as the cleft palate gene on 2q32-q33. Hum. Mol. Genet. 2003;12:2491–2501. doi: 10.1093/hmg/ddg248. PubMed DOI

Dobreva G, Dambacher J, Grosschedl R. SUMO modification of a novel MAR-binding protein, SATB2, modulates immunoglobulin mu gene expression. Genes. Dev. 2003;17:3048–3061. doi: 10.1101/gad.1153003. PubMed DOI PMC

Britanova O, et al. Satb2 haploinsufficiency phenocopies 2q32-q33 deletions, whereas loss suggests a fundamental role in the coordination of jaw development. Am. J. Hum. Genet. 2006;79:668–678. doi: 10.1086/508214. PubMed DOI PMC

Gu W, et al. SATB2 preserves colon stem cell identity and mediates ileum-colon conversion via enhancer remodeling. Cell Stem Cell. 2022;29:101–115. doi: 10.1016/j.stem.2021.09.004. PubMed DOI PMC

Conner JR, Hornick JL. SATB2 is a novel marker of osteoblastic differentiation in bone and soft tissue tumours. Histopathology. 2013;63:36–49. doi: 10.1111/his.12138. PubMed DOI

Owosho AA, et al. SATB2 and MDM2 immunoexpression and diagnostic role in primary osteosarcomas of the jaw. Dent. J. (Basel). 2021 doi: 10.3390/dj10010004. PubMed DOI PMC

Magnusson K, et al. SATB2 in combination with cytokeratin 20 identifies over 95% of all colorectal carcinomas. Am. J. Surg. Pathol. 2011;35:937–948. doi: 10.1097/PAS.0b013e31821c3dae. PubMed DOI

Dragomir A, de Wit M, Johansson C, Uhlen M, Pontén F. The role of SATB2 as a diagnostic marker for tumors of colorectal origin: Results of a pathology-based clinical prospective study. Am. J. Clin. Pathol. 2014;141:630–638. doi: 10.1309/AJCPWW2URZ9JKQJU. PubMed DOI

Lin F, et al. Cadherin-17 and SATB2 are sensitive and specific immunomarkers for medullary carcinoma of the large intestine. Arch. Pathol. Lab. Med. 2014;138:1015–1026. doi: 10.5858/arpa.2013-0452-OA. PubMed DOI

Berg KB, Schaeffer DF. SATB2 as an immunohistochemical marker for colorectal adenocarcinoma: A concise review of benefits and pitfalls. Arch. Pathol. Lab. Med. 2017;141:1428–1433. doi: 10.5858/arpa.2016-0243-RS. PubMed DOI

Ma C, Lowenthal BM, Pai RK. SATB2 is superior to CDX2 in distinguishing signet ring cell carcinoma of the upper gastrointestinal tract and lower gastrointestinal tract. Am. J. Surg. Pathol. 2018;42:1715–1722. doi: 10.1097/PAS.0000000000001159. PubMed DOI

Yang C, et al. Diagnostic utility of SATB2 in metastatic krukenberg tumors of the ovary: An immunohistochemical study of 70 cases with comparison to CDX2, CK7, CK20, chromogranin, and synaptophysin. Am. J. Surg. Pathol. 2018;42:160–171. doi: 10.1097/PAS.0000000000000951. PubMed DOI

Wang S, et al. Down-regulated expression of SATB2 is associated with metastasis and poor prognosis in colorectal cancer. J. Pathol. 2009;219:114–122. doi: 10.1002/path.2575. PubMed DOI

Eberhard J, et al. A cohort study of the prognostic and treatment predictive value of SATB2 expression in colorectal cancer. Br. J. Cancer. 2012;106:931–938. doi: 10.1038/bjc.2012.34. PubMed DOI PMC

Mezheyeuski A, et al. Metastatic colorectal carcinomas with high SATB2 expression are associated with better prognosis and response to chemotherapy: A population-based Scandinavian study. Acta. Oncol. 2020;59:284–290. doi: 10.1080/0284186X.2019.1691258. PubMed DOI

Schmitt M, et al. Loss of SATB2 occurs more frequently than CDX2 loss in colorectal carcinoma and identifies particularly aggressive cancers in high-risk subgroups. Cancers (Basel). 2021;13:6177. doi: 10.3390/cancers13246177. PubMed DOI PMC

Kummar S, Fogarasi M, Canova A, Mota A, Ciesielski T. Cytokeratin 7 and 20 staining for the diagnosis of lung and colorectal adenocarcinoma. Br. J. Cancer. 2002;86:1884–1887. doi: 10.1038/sj.bjc.6600326. PubMed DOI PMC

Park SY, Kim HS, Hong EK, Kim WH. Expression of cytokeratins 7 and 20 in primary carcinomas of the stomach and colorectum and their value in the differential diagnosis of metastatic carcinomas to the ovary. Hum. Pathol. 2002;33:1078–1085. doi: 10.1053/hupa.2002.129422. PubMed DOI

Zhang PJ, Shah M, Spiegel GW, Brooks JJ. Cytokeratin 7 immunoreactivity in rectal adenocarcinomas. Appl. Immunohistochem. Mol. Morphol. 2003;11:306–310. doi: 10.1097/00129039-200312000-00005. PubMed DOI

McGregor DK, Wu TT, Rashid A, Luthra R, Hamilton SR. Reduced expression of cytokeratin 20 in colorectal carcinomas with high levels of microsatellite instability. Am. J. Surg. Pathol. 2004;28:712–718. doi: 10.1097/01.pas.0000126757.58474.12. PubMed DOI

Hernandez BY, et al. CK20 and CK7 protein expression in colorectal cancer: demonstration of the utility of a population-based tissue microarray. Hum. Pathol. 2005;36:275–281. doi: 10.1016/j.humpath.2005.01.013. PubMed DOI

Lugli A, Tzankov A, Zlobec I, Terracciano LM. Differential diagnostic and functional role of the multi-marker phenotype CDX2/CK20/CK7 in colorectal cancer stratified by mismatch repair status. Mod. Pathol. 2008;21:1403–1412. doi: 10.1038/modpathol.2008.117. PubMed DOI

Saad RS, Silverman JF, Khalifa MA, Rowsell C. CDX2, cytokeratins 7 and 20 immunoreactivity in rectal adenocarcinoma. Appl. Immunohistochem. Mol. Morphol. 2009;17:196–201. doi: 10.1097/PAI.0b013e31819268f2. PubMed DOI

Bayrak R, Yenidünya S, Haltas H. Cytokeratin 7 and cytokeratin 20 expression in colorectal adenocarcinomas. Pathol. Res. Pract. 2011;207:156–160. doi: 10.1186/1746-1596-7-9. PubMed DOI

Harbaum L, et al. Keratin 7 expression in colorectal cancer—Freak of nature or significant finding? Histopathology. 2011;59:225–234. doi: 10.1111/j.1365-2559.2011.03694.x. PubMed DOI

Bayrak R, Haltas H, Yenidunya S. The value of CDX2 and cytokeratins 7 and 20 expression in differentiating colorectal adenocarcinomas from extraintestinal gastrointestinal adenocarcinomas: Cytokeratin 7−/20+ phenotype is more specific than CDX2 antibody. Diagn. Pathol. 2012;7:9. doi: 10.1186/1746-1596-7-9. PubMed DOI PMC

Gurzu S, Jung I. Aberrant pattern of the cytokeratin 7/cytokeratin 20 immunophenotype in colorectal adenocarcinomas with BRAF mutations. Pathol. Res. Pract. 2012;208:163–166. doi: 10.1016/j.prp.2012.01.003. PubMed DOI

Yamagishi H, et al. Aberrant cytokeratin expression as a possible prognostic predictor in poorly differentiated colorectal carcinoma. J. Gastroenterol. Hepatol. 2013;28:1815–1822. doi: 10.1111/jgh.12319. PubMed DOI

Landau MS, Kuan SF, Chiosea S, Pai RK. BRAF-mutated microsatellite stable colorectal carcinoma: An aggressive adenocarcinoma with reduced CDX2 and increased cytokeratin 7 immunohistochemical expression. Hum. Pathol. 2014;45:1704–1712. doi: 10.1016/j.humpath.2014.04.008. PubMed DOI

Droy-Dupré L, Bossard C, Volteau C, Bezieau S, Laboisse CL, Mosnier JF. Hierarchical clustering identifies a subgroup of colonic adenocarcinomas expressing crypt-like differentiation markers, associated with MSS status and better prognosis. Virchows Arch. 2015;466:383–391. doi: 10.1007/s00428-015-1724-9. PubMed DOI

Al-Maghrabi J, Emam E, Gomaa W. Immunohistochemical staining of cytokeratin 20 and cytokeratin 7 in colorectal carcinomas: Four different immunostaining profiles. Saudi J. Gastroenterol. 2018;24:129–134. doi: 10.4103/sjg.SJG_465_17. PubMed DOI PMC

Loupakis F, et al. CK7 and consensus molecular subtypes as major prognosticators in V600EBRAF mutated metastatic colorectal cancer. Br. J. Cancer. 2019;121:593–599. doi: 10.1038/s41416-019-0560-0. PubMed DOI PMC

Fei F, et al. CK7 expression associates with the location, differentiation, lymph node metastasis, and the Dukes' stage of primary colorectal cancers. J. Cancer. 2019;10:2510–2519. doi: 10.7150/jca.29397. PubMed DOI PMC

Tamura T, et al. Programmed death-1 ligand-1 (PDL1) expression is associated with the prognosis of patients with stage II/III gastric cancer. Anticancer Res. 2015;35:5369–5376. PubMed

Zhang L, et al. Programmed cell death ligand 1 (PD-L1) expression on gastric cancer and its relationship with clinicopathologic factors. Int. J. Clin. Exp. Pathol. 2015;8:11084–11091. PubMed PMC

Eto S, et al. Programmed cell death protein 1 expression is an independent prognostic factor in gastric cancer after curative resection. Gastric Cancer. 2016;19:466–471. doi: 10.1007/s10120-015-0519-7. PubMed DOI

Gu L, et al. PD-L1 and gastric cancer prognosis: A systematic review and meta-analysis. PLoS ONE. 2017;12:e0182692. doi: 10.1371/journal.pone.0182692. PubMed DOI PMC

Tanaka K, et al. Negative influence of programmed death-1-ligands on the survival of esophageal cancer patients treated with chemotherapy. Cancer Sci. 2016;107:726–733. doi: 10.1111/cas.12938. PubMed DOI PMC

Yagi T, et al. PD-L1 expression, tumor-infiltrating lymphocytes, and clinical outcome in patients with surgically resected esophageal cancer. Ann. Surg. 2019;269:471–478. doi: 10.1097/SLA.0000000000002616. PubMed DOI

Luchini C, et al. PD-1, PD-L1, and CD163 in pancreatic undifferentiated carcinoma with osteoclast-like giant cells: expression patterns and clinical implications. Hum. Pathol. 2018;81:157–165. doi: 10.1016/j.humpath.2018.07.006. PubMed DOI

Hrudka J, Lawrie K, Waldauf P, Ciprová V, Moravcová J, Matěj R. Negative prognostic impact of PD-L1 expression in tumor cells of undifferentiated (anaplastic) carcinoma with osteoclast-like giant cells of the pancreas: Study of 13 cases comparing ductal pancreatic carcinoma and review of the literature. Virchows Arch. 2020;477:687–696. doi: 10.1007/s00428-020-02830-8. PubMed DOI

Shi SJ, et al. B7–H1 expression is associated with poor prognosis in colorectal carcinoma and regulates the proliferation and invasion of HCT116 colorectal cancer cells. PLoS ONE. 2013;8:e76012. doi: 10.1371/journal.pone.0076012. PubMed DOI PMC

Zhu H, et al. Clinical significance of programmed death ligand-1 (PD-L1) in colorectal serrated adenocarcinoma. Int. J. Clin. Exp. Pathol. 2015;8:9351–9359. PubMed PMC

Lee LH, et al. Patterns and prognostic relevance of PD-1 and PD-L1 expression in colorectal carcinoma. Mod. Pathol. 2016;29:1433–1442. doi: 10.1038/modpathol.2016.139. PubMed DOI PMC

Rosenbaum MW, Bledsoe JR, Morales-Oyarvide V, Huynh TG, Mino-Kenudson M. PD-L1 expression in colorectal cancer is associated with microsatellite instability, BRAF mutation, medullary morphology and cytotoxic tumor-infiltrating lymphocytes. Mod. Pathol. 2016;29:1104–1112. doi: 10.1038/modpathol.2016.95. PubMed DOI

Saigusa S, et al. Implication of programmed cell death ligand 1 expression in tumor recurrence and prognosis in rectal cancer with neoadjuvant chemoradiotherapy. Int. J. Clin. Oncol. 2016;21:946–952. doi: 10.1007/s10147-016-0962-4. PubMed DOI

Enkhbat T, et al. Programmed cell death ligand 1 expression is an independent prognostic factor in colorectal cancer. Anticancer Res. 2018;38:3367–3373. doi: 10.21873/anticanres.12603. PubMed DOI

Koganemaru S, et al. Prognostic value of programmed death-ligand 1 expression in patients with stage III colorectal cancer. Cancer Sci. 2017;108:853–858. doi: 10.1111/cas.13229. PubMed DOI PMC

Shao L, et al. Tumor cell PD-L1 predicts poor local control for rectal cancer patients following neoadjuvant radiotherapy. Cancer Manag. Res. 2017;9:249–258. doi: 10.2147/CMAR.S139889. PubMed DOI PMC

Lee KS, et al. Programmed cell death ligand-1 protein expression and CD274/PD-L1 gene amplification in colorectal cancer: Implications for prognosis. Cancer Sci. 2018;109:2957–2969. doi: 10.1111/cas.13716. PubMed DOI PMC

Ho HL, et al. PD-L1 is a double-edged sword in colorectal cancer: the prognostic value of PD-L1 depends on the cell type expressing PD-L1. J. Cancer Res. Clin. Oncol. 2019;145:1785–1794. doi: 10.1007/s00432-019-02942-y. PubMed DOI PMC

Wu Z, et al. Prognostic impact of adenosine receptor 2 (A2aR) and programmed cell death ligand 1 (PD-L1) expression in colorectal cancer. Biomed. Res. Int. 2019;2019:8014627. doi: 10.1155/2019/8014627. PubMed DOI PMC

Chen YL, Wang GX, Lin BA, Huang JS. MicroRNA-93-5p expression in tumor tissue and its tumor suppressor function via targeting programmed death ligand-1 in colorectal cancer. Cell Biol. Int. 2020;44:1224–1236. doi: 10.1002/cbin.11323. PubMed DOI

Wang S, et al. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: A meta-analysis. Int. J. Colorectal. Dis. 2021;36:117–130. doi: 10.1007/s00384-020-03734-4. PubMed DOI PMC

Hrudka J, Fišerová H, Jelínková K, Matěj R, Waldauf P. Cytokeratin 7 expression as a predictor of an unfavorable prognosis in colorectal carcinoma. Sci. Rep. 2021;11:17863. doi: 10.1038/s41598-021-97480-4. PubMed DOI PMC

Brierley JD, Gospodarowicz MK, Wittekind C. TNM Classification of Malignant Tumors. 8. Wiley Blackwell; 2017. pp. 73–76.

R Core Team. R: A language and environment for statistical computing. R Foundation for Statistical Computing, (Vienna, Austria 2019). https://www.R-project.org/. Accessed Dec 2021.

Therneau, T. A Package for Survival Analysis in R. version 3.1–7 (2015). https://CRAN.R-project.org/package=survival. Accessed Dec 2021.

Chung J, et al. SATB2 augments ΔNp63α in head and neck squamous cell carcinoma. EMBO Rep. 2010;11:777–783. doi: 10.1038/embor.2010.125. PubMed DOI PMC

Dobreva G, et al. SATB2 is a multifunctional determinant of craniofacial patterning and osteoblast differentiation. Cell. 2006;125:971–986. doi: 10.1016/j.cell.2006.05.012. PubMed DOI

Han HJ, Russo J, Kohwi Y, Kohwi-Shigematsu T. SATB1 reprogrammes gene expression to promote breast tumour growth and metastasis. Nature. 2008;452:187–193. doi: 10.1038/nature06781. PubMed DOI

Meng WJ, et al. Correlation of SATB1 overexpression with the progression of human rectal cancer. Int. J. Colorectal. Dis. 2012;27:143–150. doi: 10.1007/s00384-011-1302-9. PubMed DOI

Kirchner T, et al. Metaplasia, intraepithelial neoplasia and early cancer of the stomach are related to dedifferentiated epithelial cells defined by cytokeratin-7 expression in gastritis. Virchows Arch. 2001;439:512–522. doi: 10.1007/s004280100477. PubMed DOI

Gong J, Chehrazi-Raffle A, Reddi S, Salgia R. Development of PD-1 and PD-L1 inhibitors as a form of cancer immunotherapy: A comprehensive review of registration trials and future considerations. J. Immunother. Cancer. 2018;6:8. doi: 10.1186/s40425-018-0316-z. PubMed DOI PMC

Lu S, et al. Comparison of biomarker modalities for predicting response to PD-1/PD-L1 checkpoint blockade: A systematic review and meta-analysis. JAMA Oncol. 2019;5:1195–1204. doi: 10.1001/jamaoncol.2019.1549. PubMed DOI PMC

Balar AV, Weber JS. PD-1 and PD-L1 antibodies in cancer: Current status and future directions. Cancer Immunol. Immunother. 2017;66:551–564. doi: 10.1007/s00262-017-1954-6. PubMed DOI PMC

Overman MJ, et al. Nivolumab in patients with metastatic DNA mismatch repair-deficient or microsatellite instability-high colorectal cancer (CheckMate 142): An open-label, multicentre, phase 2 study. Lancet Oncol. 2017;18:1182–1191. doi: 10.1016/S1470-2045(17)30422-9. PubMed DOI PMC

Li Y, et al. Prognostic impact of programed cell death-1 (PD-1) and PD-ligand 1 (PD-L1) expression in cancer cells and tumor infiltrating lymphocytes in colorectal cancer. Mol. Cancer. 2016;15:55. doi: 10.1186/s12943-016-0539-x. PubMed DOI PMC

Calik I, et al. Intratumoral cytotoxic T-lymphocyte density and PD-L1 expression are prognostic biomarkers for patients with colorectal cancer. Medicina (Kaunas). 2019;55:723. doi: 10.3390/medicina55110723. PubMed DOI PMC

Chen TW, Huang KC, Chiang SF, Chen WT, Ke TW, Chao KSC. Prognostic relevance of programmed cell death-ligand 1 expression and CD8+ TILs in rectal cancer patients before and after neoadjuvant chemoradiotherapy. J. Cancer Res. Clin. Oncol. 2019;145:1043–1053. doi: 10.1007/s00432-019-02874-7. PubMed DOI PMC

Lee KS, et al. Prognostic implication of CD274 (PD-L1) protein expression in tumor-infiltrating immune cells for microsatellite unstable and stable colorectal cancer. Cancer Immunol. Immunother. 2017;66:927–939. doi: 10.1007/s00262-017-1999-6. PubMed DOI PMC

Berntsson J, Eberhard J, Nodin B, Leandersson K, Larsson AH, Jirström K. Expression of programmed cell death protein 1 (PD-1) and its ligand PD-L1 in colorectal cancer: Relationship with sidedness and prognosis. Oncoimmunology. 2018;7:e1465165. doi: 10.1080/2162402X.2018.1465165. PubMed DOI PMC

Ogura A, et al. Pattern of programmed cell death-ligand 1 expression and CD8-positive T-cell infiltration before and after chemoradiotherapy in rectal cancer. Eur. J. Cancer. 2018;91:11–20. doi: 10.1016/j.ejca.2017.12.005. PubMed DOI

Eriksen AC, et al. Programmed Death Ligand-1 expression in stage II colon cancer—Experiences from a nationwide populationbased cohort. BMC Cancer. 2019;19:142. doi: 10.1186/s12885-019-5345-6. PubMed DOI PMC

Wyss J, et al. Stromal PD-1/PD-L1 expression predicts outcome in colon cancer patients. Clin. Colorectal Cancer. 2019;18:e20–e38. doi: 10.1016/j.clcc.2018.09.007. PubMed DOI

Shen Z, Gu L, Mao D, Chen M, Jin R. Clinicopathological and prognostic significance of PD-L1 expression in colorectal cancer: A systematic review and meta-analysis. World J. Surg. Oncol. 2019;17:4. doi: 10.1186/s12957-018-1544-x. PubMed DOI PMC

Alexander PG, McMillan DC, Park JH. A meta-analysis of CD274 (PD-L1) assessment and prognosis in colorectal cancer and its role in predicting response to anti-PD-1 therapy. Crit. Rev. Oncol. Hematol. 2021;157:103147. doi: 10.1016/j.critrevonc.2020.103147. PubMed DOI

Sul J, Blumenthal GM, Jiang X, He K, Keegan P, Pazdur R. FDA approval summary: Pembrolizumab for the treatment of patients with metastatic non-small cell lung cancer whose tumors express programmed death-ligand 1. Oncologist. 2016;21:643–650. doi: 10.1634/theoncologist.2015-0498. PubMed DOI PMC

Hui R, et al. Long-term OS for patients with advanced NSCLC enrolled in the KEYNOTE-001 study of pembrolizumab (pembro) J. Clin. Oncol. 2016;34:15. doi: 10.1200/JCO.2016.34.15_suppl.9026. DOI

Reck M, et al. Pembrolizumab versus chemotherapy for PD-L1-positive non-small-cell lung cancer. N. Engl. J. Med. 2016;375:1823–1833. doi: 10.1056/NEJMoa1606774. PubMed DOI

Kreidieh M, Mukherji D, Temraz S, Shamseddine A. Expanding the scope of immunotherapy in colorectal cancer: Current clinical approaches and future directions. Biomed. Res. Int. 2020;2020:9037217. doi: 10.1155/2020/9037217. PubMed DOI PMC

Wei XL, et al. The Clinical and biomarker association of programmed death ligand 1 and its spatial heterogeneous expression in colorectal cancer. J. Cancer. 2018;9:4325–4333. doi: 10.7150/jca.27735. PubMed DOI PMC

Jourdan F, et al. Tissue microarray technology: Validation in colorectal carcinoma and analysis of p53, hMLH1, and hMSH2 immunohistochemical expression. Virchows Arch. 2003;443:115–121. doi: 10.1007/s00428-003-0833-z. PubMed DOI

Park Y, et al. PD-L1 testing in gastric cancer by the combined positive score of the 22C3 PharmDx and SP263 assay with clinically relevant cut-offs. Cancer. Res. Treat. 2020;52:661–670. doi: 10.4143/crt.2019.718. PubMed DOI PMC

Ahn S, Kim KM. PD-L1 expression in gastric cancer: interchangeability of 22C3 and 28–8 pharmDx assays for responses to immunotherapy. Mod. Pathol. 2021;34:1719–1727. doi: 10.1038/s41379-021-00823-9. PubMed DOI

De Marchi P, et al. PD-L1 expression by Tumor Proportion Score (TPS) and Combined Positive Score (CPS) are similar in non-small cell lung cancer (NSCLC) J. Clin. Pathol. 2021;74:735–740. doi: 10.1136/jclinpath-2020-206832. PubMed DOI

Noske A, et al. Interassay and interobserver comparability study of four programmed death-ligand 1 (PD-L1) immunohistochemistry assays in triple-negative breast cancer. Breast. 2021;60:238–244. doi: 10.1016/j.breast.2021.11.003. PubMed DOI PMC

Nuti S, et al. High interobserver and intraobserver reproducibility among pathologists assessing PD-L1 CPS across multiple indications. Histopathology. 2022 doi: 10.1111/his.14775. PubMed DOI

Molecular genetic analysis of colorectal carcinoma with an aggressive extraintestinal immunohistochemical phenotype